TriSalus Life Sciences (NASDAQ:TLSI) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of TriSalus Life Sciences (NASDAQ:TLSI) from a hold rating to a sell rating in a research note published on Sunday.

TLSI has been the topic of a number of other research reports. Canaccord Genuity Group raised their target price on TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Zacks Research upgraded shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $11.00.

TriSalus Life Sciences Price Performance

Shares of TLSI opened at $4.75 on Friday. The company has a market capitalization of $237.31 million, a PE ratio of -2.35 and a beta of 0.42. TriSalus Life Sciences has a one year low of $3.42 and a one year high of $7.95. The company’s fifty day moving average price is $6.23 and its 200 day moving average price is $5.27.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.79). The business had revenue of $11.57 million for the quarter, compared to the consensus estimate of $11.76 million. Analysts anticipate that TriSalus Life Sciences will post -1.55 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC acquired a new stake in TriSalus Life Sciences during the second quarter valued at approximately $10,900,000. AWM Investment Company Inc. acquired a new position in shares of TriSalus Life Sciences in the 2nd quarter worth approximately $6,812,000. Vanguard Group Inc. lifted its position in shares of TriSalus Life Sciences by 42.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock worth $5,392,000 after buying an additional 345,186 shares during the period. Gilder Gagnon Howe & Co. LLC boosted its stake in TriSalus Life Sciences by 32.1% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after buying an additional 265,618 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in TriSalus Life Sciences by 107.4% in the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock valued at $2,480,000 after buying an additional 235,627 shares in the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.